Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
MWN-AI** Summary
Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical-stage biopharmaceutical company dedicated to developing innovative precision medicines for oncology, is set to host a virtual Key Opinion Leader Meeting on December 2, 2025, at 8:00 AM ET. The session will focus on the NXP900 Phase 1b clinical program, particularly its application in advanced solid tumors and in combination with osimertinib for non-small cell lung cancer (NSCLC).
The meeting will feature distinguished experts, Dr. Alexander Spira, Chief Scientific Officer of NEXT Oncology, and Dr. Asier Uncita-Broceta, Professor of Chemistry at the University of Edinburgh. They will discuss critical insights from preclinical and clinical trials of NXP900, as well as the overall strategy for the ongoing Phase 1b program. A live question-and-answer segment will allow attendees to engage with the speakers directly. Interested participants can register for the event online.
NXP900 stands out as an orally administered small molecule inhibitor that targets SRC Family Kinases (SFK), specifically YES1 and SRC. By inhibiting both the catalytic and scaffolding functions of the SRC pathway, NXP900 aims to counter adverse effects often seen with traditional inhibitors. Following a successful Phase 1a dose escalation study, Nuvectis is advancing to a Phase 1b single-agent expansion in patients with pathogenic mutations, with a combination treatment arm anticipated to commence by year-end 2025.
Nuvectis Pharma is not only committed to NXP900 but is also exploring advancements with their other candidate, NXP800, targeting ARID1a-mutated ovarian cancer. For further details, interested parties are encouraged to refer to Nuvectis Pharma's website or connect with company representatives.
MWN-AI** Analysis
As Nuvectis Pharma (NASDAQ: NVCT) prepares to host its virtual Key Opinion Leader (KOL) meeting on December 2, 2025, investor attention should sharpen on the company's innovative NXP900 Phase 1b program in advanced solid tumors, particularly in combination with osimertinib for non-small cell lung cancer (NSCLC). This event will present insights from esteemed experts, Dr. Alexander Spira and Dr. Asier Uncita-Broceta, shedding light on NXP900’s promising clinical data and development strategy.
The timing of this meeting aligns well with an increasing focus on targeted therapies in oncology. NXP900, a selective oral small molecule SRC kinase inhibitor, targets both the catalytic and scaffolding functions of the SRC pathway, which could potentially leverage significant efficacy against advanced solid tumors with specific genetic mutations. Given the growing prevalence of NSCLC and the limitations of current therapies, particularly in treatment-resistant cases, Nuvectis could position itself favorably within this competitive landscape.
Investors should closely monitor the data shared during the KOL meeting and any implications for ongoing clinical trials. The anticipated initiation of enrollment in the Phase 1b dose expansion combination arm may catalyze further interest in the stock, particularly if early results indicate enhanced efficacy over existing treatments.
The broader oncology market remains dynamic, with therapeutic advancements and regulatory shifts impacting valuations. As Nuvectis continues to carve out its niche, savvy investors might consider integrating NVCT into their portfolios, particularly if the KOL meeting yields favorable data that could bolster investor confidence. Underpinning investment in Nuvectis is its commitment to addressing unmet medical needs and driving innovation in precision medicine, a sector poised for substantial growth.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, including the combination with osimertinib in non-small cell lung cancer. To register for the event, click here .
The event will feature Alexander Spira, MD, PhD, FACP, FASCO (Chief Scientific Officer, NEXT Oncology) and Asier Uncita-Broceta, MPharm, MSc, PhD (Professor of Chemistry, University of Edinburgh) who will join Company management to discuss the NXP900 development program. The discussion will focus on key NXP900 preclinical and clinical data to date and the strategy for the monotherapy and combination components of the NXP900 Phase 1b clinical program.
A live question and answer session will follow the formal presentation. A replay of the webinar will be available on the Investors section of the Nuvectis website at https://nuvectis.com/investors/ .
About Dr. Alexander Spira, MD, PhD, FACP, FASCO
Dr. Alexander Spira is the Chief Scientific Officer of NEXT Oncology. He serves as Chair of the US Oncology Research Executive Committee and is a member of US Oncology National Policy Board Executive Committee. He is also a faculty member at Johns Hopkins School of Medicine, where he is an Assistant Professor of Oncology. He has authored many important manuscripts in highly prestigious journals such as the New England Journal of Medicine, Journal of Clinical Research, and Clinical Cancer Research, involving innovative new therapies for the treatment of cancer. In addition to his work with NEXT Oncology, Dr. Spira is deeply engaged in advancing targeted cancer treatments through Phase 1 clinical trials. His areas of interest include immunotherapy, personalized medicine, gastrointestinal cancers, thoracic and lung cancers, and sarcomas. Recognized as a “Top Doctor” by both Northern Virginia Magazine and Washingtonian Magazine, Dr. Spira received the prestigious Castle Connolly “America’s Top Doctor” award in 2014. Dr. Spira will continue to serve as the Co-Director, Virginia Cancer Specialists’ Research Institute, and Director of Virginia Cancer Specialists’ Thoracic and Phase I Program. Dr. Spira earned his medical degree from the New York University School of Medicine, completing his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. Dr. Spira also received his PhD from the New York School of Arts and Sciences.
About Professor Asier Uncita-Broceta, MPharm, MSc, PhD
Dr. Asier Uncita-Broceta received his PhD in Medicinal Chemistry from the Universidad of Granada (Spain) in 2004 and completed his postdoctoral training in the fields of cell delivery and chemical biology in the School of Chemistry of the University of Edinburgh. He joined the Cancer Research UK Edinburgh Centre as a group leader in 2010, where he established the Innovative Therapeutics Lab in 2010 (first chemistry lab of the Institute). Asier was promoted to Reader in 2015 and Full Professor in 2018. Asier is an Elected Member of the RSE Young Academy of Scotland, Associate Editor of Frontiers in Chemistry and Editorial Board Member of Scientific Reports. He is PI of Edinburgh Drug Discovery and Chemistry Director of the Edinburgh Cancer Discovery Unit. Among his awards highlight the CRUK Pioneer Award 2015, the EPSRC Healthcare Technology Challenge Award 2015 and the RSE/Patrick Neill Medal 2016.
About NXP900
NXP900 is a selective orally administered small molecule type 1.5 SRC/YRS1 kinase inhibitor. NXP900’s unique mechanism of action was designed to completely shut-down the YES1/SRC pathway by inhibiting both the catalytic and scaffolding functions of the SRC pathway, while avoiding paradoxical activation of pro-oncogenic signaling, a phenomenon observed with type 1 inhibitors.
NXP900 completed a Phase 1a dose escalation study in patients with advanced solid tumors. A Phase 1b single agent dose expansion study is underway in patients with advanced solid tumors with pathogenic mutations. Data from a recently completed drug-drug interaction study support initiation of enrollment in the Phase 1b dose expansion combination arm, anticipated to begin by YE 2025.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company's lead drug candidate, NXP900, is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900’s unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study and is being evaluated in a Phase 1b program. The Company is also considering next steps for NXP800, an oral small molecule GCN2 activator that has demonstrated anti-cancer activity in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer. For additional information about Nuvectis Pharma please visit: https://nuvectis.com/ .
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ**
What specific preclinical and clinical data will Nuvectis Pharma Inc. NVCT present during the Key Opinion Leader Meeting regarding the NXP900 Phase program for advanced solid tumors?
How does Nuvectis Pharma Inc. NVCT plan to differentiate NXP900 from other SRC inhibitors currently in development for oncology treatments?
Can you elaborate on the anticipated timeline for patient enrollment in the Phase 1b dose expansion combination arm of NXP900 at Nuvectis Pharma Inc. NVCT?
What potential implications do the findings from the ongoing NXP900 studies hold for future drug development at Nuvectis Pharma Inc. NVCT, particularly in relation to osimertinib for non-small cell lung cancer?
**MWN-AI FAQ is based on asking OpenAI questions about Nuvectis Pharma Inc. (NASDAQ: NVCT).
NASDAQ: NVCT
NVCT Trading
0.0% G/L:
$8.14 Last:
22,545 Volume:
$8.08 Open:
